ACEi, ARBs the Change in Creatinine, and the Future Risk of Outcomes — NephJC ACEi, ARBs, the increase in creatinine and health outcomes: Now for some retrospective data.

This also makes for interesting reading

www.nephjc.com/news/2017/4/...

Rodby and I had quite a fun argument

The RushRenalRules are to pay eternal homage to ACEi

#NephJC

T0e: STOP-ACEi was a multicenter, open-label trial that randomized 411 patients with advanced CKD to continue or discontinue therapy with RASi, with a follow-up of 3 yrs

STOP-ACEi trial did not find any benefit of stopping ACEi/ARBs in advanced CKD #NephJC

www.nephjc.com/news/...

T0b:
Renin-angiotensin inhibition (RASi) use is challenging in patients with advanced stages of CKD

😱The fear of hyperkalemia or overall worsening of CKD makes some clinicians moderate or terminate their use of RASi in CKD 4/5

Infographic by @priti899.bsky.social
#NephJC

👀 ¿Qué papel juegan los IECA/ARA-II en la ERC avanzada? Revisa el VA creado por @drnikhil.bsky.social, traducir por @dramiliflores.bsky.social

#NephJC

www.nephjc.com/news/...

Hi everyone

This is Santhoshi, joining from Boston to learn about RAASi in advanced CKD.

No COI

#NephJC
#NephEdC